Lipids & metabolic liver disease
Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study
Main finding · AKIResult — go to the resultOdds ratio 3.503 95% CI 1.743–7.040Authors' conclusion
Long-chain and very-long-chain ceramide levels may help determine the high AKI risk beyond traditional assessments.
Study context
- Population
- Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention, Prospective Multicenter Study for Early Evaluation of Acute Chest Pain
- Participants
- 842 patients
- Exposure
- Plasma ceramide levels at admission and acute kidney injury (AKI) risk
- Outcome
- AKI (2012 KDIGO criteria)
- Follow-up
- During hospitalisation
Methodological detailsmulticenter
- Multicenter
Main finding
AKI
Odds ratio
3.503
95% CI 1.743–7.040
P < 0.001
Cer(d18:1/24:2) Q4vs Q1
OR 3.503 (95% CI 1.743–7.040); P < 0.001
As reported in the abstract
- Developed AKI during hospitalisation
- 139 (16.5%)
Observational data: associations, not effects.
Further findings
Discrimination for AKI (AUC)
- AUC of ceramides for AKI (P < 0.001)
- 0.581-0.661
- AUC of Mehran risk score alone
- 0.780
- AUC of each ceramide combined with Mehran risk score, greater than Mehran score alone
- 0.802-0.808
Original publication
Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study. Cardiovasc Diabetol. Published 20 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →